News Source: Uinta County News
| about 1 month ago
Gaucher disease drug candidate Plicera failed to demonstrate clinically meaningful improvements in key measures of disease in 17 of 18 patients who completed the open-label Phase II study. On a somewhat positive note, the drug did increase the target...
News Source: Fox News
| about 1 month ago
Shire Pharmaceutical was cut to neutral from buy on Tuesday at UBS, which said there is only limited upside to current share prices. UBS the market has mostly priced in expected earnings from Shire's Velaglucerase, a drug used to treat Gaucher...